摘要
目的观察亚砷酸联合反应停、维生素C治疗难治性、复发性、多发性骨髓瘤(MM)患者的临床效果。方法以2008年1月至2012年1月在我院接受救治的难治性、复发性、多发性骨髓瘤患者52例为研究对象,结合患者入院时间先后分为两组,分别给予常规MP(马法兰联合泼尼松)方案治疗(对照组26例)以及亚坤酸联合反应停、维生素C治疗(观察组26例),对比两组患者治疗效果差异,同时观察患者治疗前后血象等临床指标差异。结果观察组总有效率为61.54%,高于对照组的30.77%(P<0.05);治疗后,观察组RBC(红细胞计数)、Hb(血红蛋白)、WBC(白细胞计数)、血清单克隆免疫球蛋白及肿瘤细胞百分数等指标优于对照组(P<0.05)。结论亚砷酸联合反应停、维生素C治疗难治性、复发性、多发性骨髓瘤患者的临床效果显著,建议推广。
Objective To observe the effect of arsenious acid combined with thalidomide and vitamin C in the treatment of refractory,recurrent,multiple myeloma（ MM）. Methods 52 cases with refractory,recurrent,multiple myeloma admitted into our hospital from January 2008 to January 2012 were selected and divided into two groups according to their admission time with 26 cases in each group. The control group was given routine MP（ melphalan combined with prednisone）,and the observation group was treated with arsenious acid combined with thalidomide and vitamin C. The difference in the curative effect of the two groups was compared,and the difference in the clinical indicators of the two groups before and after treatment,such as hemogram,was observed. Results The total effective rate of the observation group was 61. 54%,higher than that of the control group which was 30. 77%（ P〈0. 05）. After treatment,the RBC,Hb,WBC,serum monoclonal immunoglobulin and percentage of tumor cell of the observation group were better than those of the control group（ P〈0. 05）. Conclusion Arsenious acid combined with thalidomide and vitamin C is of remarkable curative effect in the treatment of refractory,recurrent,multiple myeloma,which is worth popularization.
作者
吕征宇
Lv Zhengyu(The Sixth People＇s Hospital of Chengdu,Chengdu 610051 China)
出处
《锦州医科大学学报》
CAS
2018年第4期36-38,共3页
Journal of Jinzhou Medical University
